What is the relationship between Carcinoembryonic Antigen (CEA) levels and adenomyosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

CEA and Adenomyosis: No Established Clinical Relationship

There is no established clinical relationship between carcinoembryonic antigen (CEA) levels and adenomyosis. CEA is a tumor marker used primarily in oncology for monitoring certain malignancies, particularly colorectal and breast cancers, while adenomyosis is a benign gynecological condition characterized by endometrial tissue within the myometrium.

CEA: Clinical Applications in Oncology

CEA is a glycoprotein produced by approximately 90% of colorectal cancers and has well-defined roles in cancer management 1:

  • Not recommended for screening, diagnosis, or staging of colorectal or breast cancers due to low sensitivity in early disease 2
  • Useful for monitoring metastatic disease during active therapy when used in conjunction with imaging, history, and physical examination 2, 3
  • Prognostic value when elevated preoperatively (≥5 ng/mL) in colorectal cancer, correlating with poorer outcomes 4
  • Surveillance monitoring recommended every 3 months for at least 3 years in stage II-III colorectal cancer patients 3, 4

Non-Malignant Conditions Affecting CEA

CEA can be elevated in various benign conditions, but adenomyosis is not among them 3:

  • Gastrointestinal conditions (gastritis, peptic ulcer disease, diverticulitis)
  • Liver diseases
  • Chronic obstructive pulmonary disease (COPD)
  • Diabetes and other metabolic disorders
  • Inflammatory states

Adenomyosis: A Distinct Benign Entity

Adenomyosis is diagnosed through imaging and histopathology, with no role for tumor markers 5, 6:

  • Imaging findings include myometrial striations, intramyometrial cystic structures, and uterine asymmetry 5
  • Clinical presentation involves abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and potential reproductive impairment 5
  • Diagnosis relies on transvaginal ultrasonography (sensitivity 77.6%) or MRI (specificity 90.0% for diffuse adenomyosis) 6
  • No tumor markers are used in the evaluation or management of adenomyosis

Clinical Pitfall to Avoid

If a patient with adenomyosis presents with an elevated CEA, this should prompt evaluation for malignancy (particularly colorectal or breast cancer) or other non-gynecological conditions that elevate CEA, rather than attributing the elevation to the adenomyosis itself 3, 1. The coexistence would be coincidental, not causally related.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of a Positive Carcinoembryonic Antigen (CEA) Test Result

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

CEA Levels in Colorectal Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.